Zhao JL, Antonarakis ES, Cheng HH, George DJ, et al. Phase 1b study of enzalutamide plus CC-115, a dual mTORC1/2 and DNA-PK inhibitor, in men with metastatic castration-resistant prostate cancer (mCRPC). Br J Cancer 2023 Nov 18. doi: 10.1038/s41416-023-02487.
PMID: 37980367